PharmaCorp Rx Inc.
PCRX.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.79% | -11.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.79% | -11.16% | |||
| Cost of Revenue | 15.24% | -14.83% | |||
| Gross Profit | 11.67% | -5.16% | |||
| SG&A Expenses | 62.28% | 5.18% | |||
| Depreciation & Amortization | 4.36% | -4.53% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.74% | -8.79% | |||
| Operating Income | -250.31% | -37.87% | |||
| Income Before Tax | -165.24% | -42.69% | |||
| Income Tax Expenses | 52.06% | 198.17% | |||
| Earnings from Continuing Operations | -257.34% | -65.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 113.95% | -133.33% | |||
| Net Income | -264.65% | -68.92% | |||
| EBIT | -250.31% | -37.87% | |||
| EBITDA | -143.39% | -27.26% | |||
| EPS Basic | -260.00% | -67.39% | |||
| Normalized Basic EPS | -169.23% | -50.00% | |||
| EPS Diluted | -260.00% | -67.39% | |||
| Normalized Diluted EPS | -169.23% | -50.00% | |||
| Average Basic Shares Outstanding | 1.73% | -1.91% | |||
| Average Diluted Shares Outstanding | 1.73% | -1.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||